Abstract:Reactive astrocytes play critical roles in the occurrence of various neurological diseases such as multiple sclerosis. Activation of astrocytes is often accompanied by a glycolysis-dominant metabolic switch. However, the role and molecular mechanism of metabolic reprogramming in activation of astrocytes have not been clarified. Here, we found that PKM2, a rate-limiting enzyme of glycolysis, displayed nuclear translocation in astrocytes of EAE (experimental autoimmune encephalomyelitis) mice, an animal model of multiple sclerosis. Prevention of PKM2 nuclear import by DASA-58 significantly reduced the activation of mice primary astrocytes, which was observed by decreased proliferation, glycolysis and secretion of inflammatory cytokines. Most importantly, we identified the ubiquitination-mediated regulation of PKM2 nuclear import by ubiquitin ligase TRIM21. TRIM21 interacted with PKM2, promoted its nuclear translocation and stimulated its nuclear activity to phosphorylate STAT3, NF-κB and interact with c-myc. Further single-cell RNA sequencing and immunofluorescence staining demonstrated that TRIM21 expression was upregulated in astrocytes of EAE. TRIM21 overexpressing in mice primary astrocytes enhanced PKM2-dependent glycolysis and proliferation, which could be reversed by DASA-58. Moreover, intracerebroventricular injection of a lentiviral vector to knockdown TRIM21 in astrocytes or intraperitoneal injection of TEPP-46, which inhibit the nuclear translocation of PKM2, effectively decreased disease severity, CNS inflammation and demyelination in EAE. Collectively, our study provides novel insights into the pathological function of nuclear glycolytic enzyme PKM2 and ubiquitination-mediated regulatory mechanism that are involved in astrocyte activation. Targeting this axis may be a potential therapeutic strategy for the treatment of astrocyte-involved neurological disease.

TRIM11 attenuates Treg cell differentiation by p62-selective autophagic degradation of AIM2

TRIM11 Suppresses AIM2 Inflammasome by Degrading AIM2 Via P62-Dependent Selective Autophagy.

Trim21 modulates endoplasmic reticulum-associated degradation and sensitizes cancer cells to ER stress-induced apoptosis by inhibiting VCP/Npl4/UFD1 assembly

Methyltransferase Setd2 Prevents T Cell-Mediated Autoimmune Diseases Via Phospholipid Remodeling

Induced TRIM21 ISGylation by IFN-β enhances p62 ubiquitination to prevent its autophagosome targeting

Trim30 Alpha Negatively Regulates Tlr-Mediated Nf-Kappa B Activation By Targeting Tab2 And Tab3 For Degradation

TRIM14 Inhibits OPTN-mediated Autophagic Degradation of KDM4D to Epigenetically Regulate Inflammation.

Selective Degradation of PU.1 During Autophagy Represses the Differentiation and Antitumour Activity of TH9 Cells.

TRIM33 plays a critical role in regulating dendritic cell differentiation and homeostasis by modulating Irf8 and Bcl2l11 transcription

TRIM 30 a negatively regulates TLR-mediated NF-j B activation by targeting TAB 2 and TAB 3 for degradation

TRIM14 Promotes Noncanonical NF‐κB Activation by Modulating p100/p52 Stability via Selective Autophagy

TRIM30α negatively regulates TLR-mediated NF-κB activation by targeting TAB2 and TAB3 for degradation

TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease

TRIM62 knockdown by inhibiting the TLR4/NF-κB pathway and NLRP3 inflammasome attenuates cognitive impairment induced by diabetes in mice

The E3 Ubiquitin Ligase TRIM65 Negatively Regulates Inflammasome Activation Through Promoting Ubiquitination of NLRP3

Trim33 Mediates the Proinflammatory Function of Th17 Cells

TRIM55 Promotes Noncanonical NF-κB Signaling and B Cell–mediated Immune Responses by Coordinating P100 Ubiquitination and Processing

AIM2 in Regulatory T Cells Restrains Autoimmune Diseases.

TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling

Pim2 Negatively Regulates T-cell Immune Responses Through Modulating Autophagy

Upregulated expression of ubiquitin ligase TRIM21 promotes PKM2 nuclear translocation and astrocyte activation in experimental autoimmune encephalomyelitis